The current standard of care for patients with Glioblastoma multiforme (GBM) is surgery, followed by radiation in combination with Temozolomide (TMZ), followed by adjuvant TMZ. The most appropriate length of treatment of adjuvant TMZ after the completion of radiation is unclear. We present the case of a 45 year old female with GBM who received adjuvant TMZ on an experimental study for 24 1-month cycles (150 mg/M2 7 days on/7 days off continuously-a higher TMZ dose than standard). After 24 months on study she was stable without GBM regrowth, but presented with a right tonsil and pharynx mass consistent with a new primary malignancy. Tonsillar biopsy was positive for Epstein–Barr virus, Cytomegalovirus and Herpes Simplex Virus, but no tumor. This case highlights the risks and possible complications of immunosuppression associated with long term TMZ use.
This is a preview of subscription content, log in to check access.
Stupp R, Mason WP et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMedGoogle Scholar
Pollack A (2009) Considering longer chemotherapy. The New York Times, New YorkGoogle Scholar
Stupp R, Hegi ME et al (2009) Effects of radiotherapy with concomitant with adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRefPubMedGoogle Scholar
Perry JR, Rizek P et al (2008) Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach. Cancer 113(8):2152–2157CrossRefPubMedGoogle Scholar
Yung WK, Prados MD et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17(9):2762–2771PubMedGoogle Scholar
Mrugala MM, Johnston SK et al (2008) Cytopenias in patients with newly diagnosed high-grade gliomas receiving radiation and temozolomide-who is at risk? Neuro Oncol 10(6):1120 (abstract P156)Google Scholar
Gerber DE, Grossman SA et al (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9(1):47–52CrossRefPubMedGoogle Scholar
Su YB, Sohn S et al (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22(4):610–616CrossRefPubMedGoogle Scholar
Georgescu G, Isola IM et al (2008) Disseminated salmonellosis in a patient treated with temozolomide. J Infect 57(5):414–415CrossRefPubMedGoogle Scholar
Hau P, Koch D et al (2007) Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 68(9):688–690CrossRefPubMedGoogle Scholar
Binello E, Germano IM (2009) Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology? J Neurooncol 94(1):145–148CrossRefPubMedGoogle Scholar
Tamm M (1999) The lung in the immunocomprised patients. Infectious complications part 2. Respiration 66(3):199–207CrossRefPubMedGoogle Scholar